

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 February 2007 (01.02.2007)

PCT

(10) International Publication Number
WO 2007/014335 A2

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61K 31/445* (2006.01)
A61K 31/47 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:
PCT/US2006/029439

(22) International Filing Date: 27 July 2006 (27.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/702,963 27 July 2005 (27.07.2005) US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).

Declaration under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATIONS COMPRISING GEMCITABINE AND TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER

(57) **Abstract:** The invention relates to a method of treating a warm-blooded animal having pancreatic cancer, in particular it relates to a method comprising administering to the warm-blooded animal having pancreatic cancer a dual inhibitor of the epidermal growth factor receptor (EGF-R) tyrosine kinase activity and the vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase activity, to a method comprising administering to the warm-blooded animal having pancreatic cancer a combination comprising (a) a compound which decrease the activity of the EGF and (b) a compound which decreases the activity of VEGF, to a combination comprising (a) a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity or, alternatively, a compound which decrease the activity of the EGF and a compound which decreases the activity of VEGF and (b) at least one compound selected from an inhibitor of the platelet derived growth factor receptor (PDGF-R) tyrosine kinase activity and antineoplastic anti-metabolites; to a method of treating a warm-blooded animal having pancreatic cancer comprising administering to the warm-blooded animal said combination; to the use of such a combination for the preparation of a medicament for the treatment of pancreatic cancer; and to a commercial package or product comprising such a combination together with instructions for the treatment of pancreatic cancer.

WO 2007/014335 A2

Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer

The invention relates to a method of treating a warm-blooded animal having pancreatic cancer, in particular it relates to a method comprising administering to the warm-blooded animal having pancreatic cancer a dual inhibitor of the epidermal growth factor receptor (EGF-R) tyrosine kinase activity and the vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase activity, to a method of treating a warm-blooded animal having pancreatic cancer comprising administering to the warm-blooded animal a combination comprising (a) a compound which decrease the activity of the EGF and (b) a compound which decreases the activity of VEGF, to a combination comprising (a) a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity or, alternatively, a compound which decrease the activity of the EGF and a compound which decreases the activity of VEGF and (b) at least one compound selected from an inhibitor of the platelet derived growth factor receptor (PDGF-R) tyrosine kinase activity and antineoplastic anti-metabolites; to a method of treating a warm-blooded animal having pancreatic cancer comprising administering to the warm-blooded animal said combination; to the use of such a combination for the preparation of a medicament for the treatment of pancreatic cancer; and to a commercial package or product comprising such a combination together with instructions for the treatment of pancreatic cancer.

Pancreatic adenocarcinoma is one of the most aggressive malignancies with most patients developing metastatic disease. Although gemcitabine can prolong survival of patients, only less than 3 % survive 5 years after the initial diagnosis and the median survival duration is less than 6 months. Clearly, there is an urgent need to develop new treatment options for pancreatic cancer.

Surprisingly, in a first aspect of the present invention it was found that simultaneous inhibition of EGFR and VEGFR inhibits the growth of human pancreatic carcinoma. In a further aspect, it was found that simultaneous inhibition of EGFR, VEGFR and, optionally, PDGFR, in combination with administration of an antineoplastic anti-metabolite inhibits very

strongly the growth of human pancreatic carcinoma and represents a perspective for prolongation of survival compared to administration of the antineoplastic anti-metabolite alone.


Hence, the present invention relates to the use of a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity or, alternatively, the use of a combination comprising (a) a compound which decrease the activity of EGF and (b) a compound which decreases the activity of VEGF for the preparation of a medicament for the treatment of pancreatic cancer.

Additionally, the present invention relates to a combination comprising (a) a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity or, alternatively, (a) a compound which decrease the activity of EGF and (b) a compound which decreases the activity of VEGF and (b) at least one compound selected from an inhibitor of the PDGF-R tyrosine kinase activity and antineoplastic anti-metabolites, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use in the treatment of pancreatic cancer.

In another aspect, the present invention pertains to a method of treating a warm-blooded animal having pancreatic cancer comprising administering to the warm-blooded animal a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity in a quantity which is therapeutically effective against pancreatic cancer in which the dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity can also be present in the form of a pharmaceutically acceptable salt as well as to a method of treating a warm-blooded animal having pancreatic cancer comprising administering to the warm-blooded animal a combination comprising (a) a compound which decrease the activity of EGF and (b) a compound which decreases the activity of VEGF in a quantity which is therapeutically effective against pancreatic cancer in which the components of the combination can also be present in the form of their pharmaceutically acceptable salts.

"Dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity" suitable for the present invention are in particular those are described in WO 03/013541,

which publication is incorporated by reference, and are 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula (I)



wherein

R_1 and R_2 are each independently of the other hydrogen, unsubstituted or substituted alkyl or cycloalkyl, a heterocyclic radical bonded via a ring carbon atom, or a radical of the formula $R_4-Y-(C=Z)-$ wherein R_4 is unsubstituted, mono- or disubstituted amino or a heterocyclic radical, Y is either not present or lower alkyl and Z is oxygen, sulfur or imino, with the proviso that R_1 and R_2 are not both hydrogen; or

R_1 and R_2 together with the nitrogen atom to which they are attached form a heterocyclic radical;

R_3 is a heterocyclic radical or an unsubstituted or substituted aromatic radical;

G is C_1-C_7 -alkylene, $-C(=O)-$, or C_1-C_6 -alkylene- $C(=O)-$ wherein the carbonyl group is attached to the NR_1R_2 moiety;

Q is $-NH-$ or $-O-$, with the proviso that Q is $-O-$ if G is $-C(=O)-$ or C_1-C_6 -alkylene- $C(=O)-$; and X is either not present or C_1-C_7 -alkylene, with the proviso that a heterocyclic radical R_3 is bonded via a ring carbon atom if X is not present;

as well as the salts of these compounds,

wherein the radicals and symbols have the meanings as defined in WO 03/013541.

In one embodiment, a particularly preferred dual EGF and VEGF protein tyrosine kinase inhibitor for use in the invention is {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-(1-[phenyl-ethyl]-amine or a pharmaceutically acceptable salt thereof.

N-phenyl-2-pyrimidine-amine derivatives as used herein are those disclosed in US 5,521,184 and US 2004-0102453. N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine can be prepared as disclosed in US 5,521,184 which publication is included into the present patent filing by reference. The monomesylate salt of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-

4-(3-pyridyl)-2-pyrimidine-amine can be prepared and formulated, e.g., as described in Examples 4 and 6 of WO 99/03854 or as described in WO03/090720, which publications are also included into the present patent filing by reference. The mesylate salt of N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine (Imatinib mesylate, ST1571) is marketed under the brand Glivec® (Gleevec®). Glivec® is a tyrosine kinase inhibitor suitable for the treatment of chronic myeloid leukemia and GIST (gastro-intestinal stromal tumors).

The term "antineoplastic anti-metabolites" includes, but is not limited to 5-fluorouracil, capecitabine, gemcitabine, methotrexate and edatrexate. Capecitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark XELODA™. Gemcitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark GEMZAR™.

Compounds which decreases the activity of VEGF are especially compounds which inhibit the VEGF receptor tyrosine kinase activity, compounds which bind to a VEGF receptor and compounds binding to VEGF, and are in particular the compounds, proteins and monoclonal antibodies generically and specifically disclosed in WO 98/35958, WO 00/09495, WO 00/27820, WO 00/59509, WO 98/11223, WO 00/27819 and EP 0 769 947; those as described by M. Prewett et al in Cancer Research 59 (1999) 5209-5218, by F. Yuan et al in Proc. Natl. Acad. Sci. USA, vol. 93, pp. 14765-14770, Dec. 1996, by Z. Zhu et al in Cancer Res. 58, 1998, 3209-3214, and by J. Mordenti et al in Toxicologic Pathology, Vol. 27, no. 1, pp 14-21, 1999; in WO 00/37502 and WO 94/10202; Angiostatin™, described by M. S. O'Reilly et al, Cell 79, 1994, 315-328; and Endostatin™, described by M. S. O'Reilly et al, Cell 88, 1997, 277-285;

compounds which decrease the activity of EGF are especially compounds which inhibit the EGF receptor tyrosine kinase activity, compounds which bind to the EGF receptor and compounds binding to EGF, and are in particular the compounds generically and specifically disclosed in WO 97/02266, EP 0 564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, US 5,747,498, WO 98/10767, WO 97/30034, WO 97/49688, WO 97/38983 and, especially, WO 96/33980;

in each case where citations of patent applications or scientific publications are given in particular in the compound claims and the final products of the working examples, the subject-matter of the final products. The pharmaceutical preparations and the claims of such patent publications is hereby incorporated into the present application by reference to this

publications. Comprised are likewise the corresponding stereoisomers as well as the corresponding crystal modifications, e.g. solvates and polymorphs, which are disclosed therein. The compounds used as active ingredients in the combinations disclosed herein can be prepared and administered as described in the cited documents, respectively.

In one embodiment, a preferred VEGF protein tyrosine kinase inhibitor for use in the invention is Avastin™ (bevacizumab). In a further embodiment, a preferred VEGF protein tyrosine kinase inhibitor for use in the invention is 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate. In one embodiment, a preferred EGF protein tyrosine kinase inhibitor for use in the invention is Iressa™ (gefitinib). In a further embodiment, a preferred EGF protein tyrosine kinase inhibitor for use in the invention is Erbitux™ (cetuximab).

The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference.

It will be understood that references to the combination partners are meant to also include the pharmaceutically acceptable salts. If the combination partners have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. A combination partners (a), (b), (c) or (d) having an acid group (for example COOH) can also form salts with bases. N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine, i.e. combination partner (a), is preferably used in the present invention in the form of its monomesylate salt (ST1571).

The combinations of the present invention can be used in the form of a combined preparation or a pharmaceutical composition.

The term "a combined preparation", as used herein defines especially a "kit of parts" in the sense that the combination partners (a) and (b) as defined above can be dosed independently or by use of different fixed combinations with distinguished amounts of the combination partners (a) and (b), i.e., simultaneously or at different time points. The parts of

the kit of parts can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts. Very preferably, the time intervals are chosen such that the effect on the treated disease in the combined use of the parts is larger than the effect which would be obtained by use of only any one of the combination partners. The ratio of the total amounts of the combination partner (a) and (b) to each other being administered in the combined preparation can be varied, e.g. in order to cope with the needs of a patient sub-population to be treated or the needs of the single patient which different needs can be due to the particular disease, age, sex, body weight, etc. of the patients. Preferably, there is at least one beneficial effect, e.g., a mutual enhancing of the effect of the combination partners (a) and (b), in particular a synergism, e.g. a more than additive effect, additional advantageous effects, less side effects, a combined therapeutic effect in a non-effective dosage of one or both of the combination partners (a) and (b), and very preferably a strong synergism of the combination partners (a) and (b).

The term "treatment" includes the treatment of a patient in need thereof resulting in a delay of progression of the solid tumor disease. The term "delay of progression" as used herein means administration of the combination to patients being in a pre-stage or in an early phase of the disease to be treated, in which patients for example a pre-form of the corresponding disease is diagnosed or which patients are in a condition, e.g. during a medical treatment or a condition resulting from an accident, under which it is likely that a corresponding disease will develop.

A combination which comprises (a) a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity or, alternatively, a compound which decrease the activity of EGF and a compound which decreases the activity of VEGF and (b) at least one compound selected from an inhibitor of the PDGF-R tyrosine kinase activity and antineoplastic anti-metabolites, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use will be referred to hereinafter as a COMBINATION OF THE INVENTION.

It can be shown by established test models and in particular those test models described herein that a COMBINATION OF THE INVENTION is suitable for the treatment of pancreatic

carcinoma. The person skilled in the pertinent art is fully enabled to select a relevant test model to prove the hereinbefore and hereinafter mentioned therapeutic indications and beneficial effects. The pharmacological activity of a COMBINATION OF THE INVENTION may, for example, be demonstrated in a clinical study or in a test procedure as essentially described hereinafter. In the studies described in the Examples, L3.6pl, a human pancreatic cancer cell, is implanted in the pancreas of nude mice. Tumor-associated endothelial cells in this model highly express phosphorylated EGFR, VEGFR, and PDGFR. Oral administration of {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-(1-[phenyl-ethyl]-amine, a dual tyrosine kinase inhibitor against EGFR and VEGFR, decreases phosphorylation of EGFR and VEGFR. PDGFR phosphorylation is inhibited by STI571. Although intraperitoneal (i.p.) injection of gemcitabine does not inhibit tumor growth, its combination with {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-(1-[phenyl-ethyl]-amine and STI571 produces >80% inhibition of tumor growth and prolongs survival in parallel with increases in number of tumor cells and tumor-associated endothelial cell apoptosis, decreased microvascular density, decreased proliferation rate, and prolonged survival. STI571 treatment also decreases pericyte coverage on tumor-associated endothelial cells. Thus, inhibiting phosphorylation of EGFR, VEGFR, and PDGFR in combination with gemcitabine enhances the efficacy of gemcitabine, resulting in inhibition of experimental human pancreatic cancer growth and significant prolongation of survival.

Suitable clinical studies in human patients are, for example, open label non-randomized, dose escalation studies in patients with pancreatic cancer. Such studies prove in particular superiority of the COMBINATION OF THE INVENTION over treatment with an antineoplastic anti-metabolite alone as well as the therapeutic efficacy of a COMBINATION OF THE INVENTION. The beneficial effects on pancreatic cancer can be determined directly through the results of these studies or by changes in the study design which are known as such to a person skilled in the art.

The COMBINATION OF THE INVENTION can also be applied in combination with surgical intervention, mild prolonged whole body hyperthermia and/or irradiation therapy.

It is one objective of this invention to provide a pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against a solid tumor disease comprising the COMBINATION OF THE INVENTION. In this composition, the combination partners (a)

and (b) can be administered together, one after the other or separately in one combined unit dosage form or in separate unit dosage forms. The unit dosage form may also be a fixed combination.

The pharmaceutical compositions for separate administration of the combination partners (a) and (b) and for the administration in a fixed combination, i.e. a single galenical compositions comprising at least two combination partners, according to the invention can be prepared in a manner known per se and are those suitable for enteral, such as oral or rectal, and parenteral administration to mammals (warm-blooded animals), including humans, comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application.

Novel pharmaceutical composition contain, for example, from about 10 % to about 100 %, preferably from about 20 % to about 60 %, of the active ingredients. Pharmaceutical preparations for the combination therapy for enteral or parenteral administration are, for example, those in unit dosage forms, such as sugar-coated tablets, tablets, capsules or suppositories, and furthermore ampoules. If not indicated otherwise, these are prepared in a manner known per se, for example by means of conventional mixing, granulating, sugar-coating, dissolving or lyophilizing processes. It will be appreciated that the unit content of a combination partner contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units.

In particular, a therapeutically effective amount of each of the combination partner of the COMBINATION OF THE INVENTION may be administered simultaneously or sequentially and in any order, and the components may be administered separately or as a fixed combination. For example, the method of treatment of pancreatic cancer according to the invention may comprise (i) administration of the combination partner (a) in free or pharmaceutically acceptable salt form and (ii) administration of the combination partner (b) in free or pharmaceutically acceptable salt form, simultaneously or sequentially in any order, in jointly therapeutically effective amounts, preferably in synergistically effective amounts, e.g. in daily dosages corresponding to the amounts described herein. The individual combination partners of the COMBINATION OF THE INVENTION can be administered separately at

different times during the course of therapy or concurrently in divided or single combination forms. Furthermore, the term administering also encompasses the use of a pro-drug of a combination partner that convert *in vivo* to the combination partner as such. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.

The effective dosage of each of the combination partners employed in the COMBINATION OF THE INVENTION may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the condition being treated, the severity of the condition being treated. Thus, the dosage regimen the COMBINATION OF THE INVENTION is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient. A physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the single active ingredients required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients' availability to target sites. When the combination partners employed in the COMBINATION OF THE INVENTION are applied in the form as marketed as single drugs, their dosage and mode of administration can take place in accordance with the information provided on the package insert of the respective marketed drug in order to result in the beneficial effect described herein, if not mentioned herein otherwise.

N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine monomesylate, is preferably administered to a human in a dosage in the range of about 25 to 1000 mg/day, more preferably 50 to 800 mg/day and most preferably 100 to 400 mg/day. Unless stated otherwise herein, the compound is preferably administered from one to four times per day.

5-Fluorouracil may be administered to a human in a dosage range varying from about 50 to 1000 mg/m²day, e.g. 500 mg/m²day.

Capecitabine may be administered to a human in a dosage range varying from about 10 to 1000 mg/m²day.

- 10 -

Gemcitabine hydrochloride may be administered to a human in a dosage range varying from about 1000 mg/week.

Methotrexate may be administered to a human in a dosage range varying from about 5 to 500 mg/m²day.

The succinate salt described in Example 62 of WO 98/35958 may be administered to a human in a dosage range of about 50 to 1500, more preferably about 100 to 750, and most preferably 250 to 500, mg/day.

Furthermore, the present invention pertains to the use of a COMBINATION OF THE INVENTION for the treatment of pancreatic cancer and for the preparation of a medicament for the treatment of pancreatic cancer.

Moreover, the present invention provides a commercial package comprising as active ingredients COMBINATION OF THE INVENTION, together with instructions for simultaneous, separate or sequential use thereof in the treatment of pancreatic cancer.

EXAMPLES

The following Example illustrates the invention described above, but is not, however, intended to limit the scope of the invention in any way. Other test models known as such to the person skilled in the pertinent art can also determine the beneficial effects of the COMBINATION OF THE INVENTION.

Pancreatic Cancer Cell Line and Culture Condition. The human pancreatic cancer cell line L3.6pl is maintained in minimal essential medium supplemented with 10% fetal bovine serum (FBS), sodium pyruvate, nonessential amino acids, L-glutamine, a twofold vitamin solution (Life Technologies, Inc., Grand Island, NY), and a penicillin-streptomycin mixture (Flow Laboratories, Rockville, MD) as described previously by Hwang et al. in Clin Cancer Res 2003;9:6534-44.

Reagents. For oral administration, {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-(1-[phenyl-ethyl])-amine is diluted in DMSO and ST1571 is diluted

in sterile water. Gemcitabine (Gemzar, Eli Lilly Co, Indianapolis, IN) is maintained at room temperature and dissolved in phosphate buffered saline (PBS) on the day of use. It is administered by i.p. injection.

Primary antibodies are purchased from the following manufacturers: rabbit anti-pVEGFR 2/3 (Flk-1) (Oncogene, Boston, MA); rabbit anti-human, mouse, rat VEGF-R(Flk-1)(C1158) (Santa Cruz Biotechnology, Santa Cruz, CA); rabbit anti-human pEGFR (Tyr 1173) (Biosource, Camarillo, CA); rabbit anti-human EGF and rabbit anti-human EGFR for paraffin samples (Santa Cruz Biotechnology); rabbit anti-human EGFR for frozen samples (Zymed, San Francisco, CA); rabbit anti-VEGF (A20) (Santa Cruz Biotechnology); polyclonal rabbit anti-PDGFR- β , polyclonal goat anti-phosphorylated PDGFR- β , and polyclonal rabbit anti-PDGF- β (all obtained from Santa Cruz Biotechnology, Santa Cruz, CA); rat anti-mouse CD31 (BD PharMingen, San Diego, CA); mouse anti-proliferating cell nuclear antigen (PCNA) clone PC 10 (Dako A/S, Copenhagen, Denmark); and rabbit anti-desmin (Dako A/S) (as a pericyte marker). The following secondary antibodies are used for colorimetric immunohistochemistry: peroxidase-conjugated goat anti-rabbit IgG; F(ab')2 (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA); biotinylated goat anti-rabbit (Biocare Medical, Walnut Creek, CA); streptavidin horseradish peroxidase (Dako A/S); rat anti-mouse IgG2a horseradish peroxidase (Serotec, Harlan Bioproducts for Science, Inc., Indianapolis, IN); and goat anti-rat horseradish peroxidase (Jackson ImmunoResearch Laboratories, Inc.). The following fluorescent secondary antibodies are used: Alexa488 conjugated goat anti-rabbit IgG (Molecular Probes Inc., Eugene, OR) and Alexa 594 conjugated goat anti-rat IgG (Molecular Probes Inc.). Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) staining is performed using a commercial apoptosis detection kit (Promeg, Madison, WI) with modifications.

Animals and Orthotopic Implantation of Tumor Cells. Male athymic nude mice (NCI-nu) are purchased from the Animal Production Area of the National Cancer Institute Frederick Cancer Research and Development Center (Frederick, MD). The mice are housed and maintained under specific pathogen-free conditions. The mice are used when they are 8 to 12 weeks old. To produce pancreatic tumors, L3.6pl cells are harvested from subconfluent cultures by a brief exposure to 0.25% trypsin and 0.02% EDTA. Trypsinization is stopped with medium containing 10% FBS, and the cells are washed once in serum-free medium and resuspended in Hanks' balanced salt solution (HBSS). Only suspensions consisting of

single cells with greater than 90% viability are used for injection into the pancreas of nude mice as described previously (Hwang et al. in Clin Cancer Res 2003;9:6534-44).

Treatment of Established Human Pancreatic Carcinoma Tumors Growing in the Pancreas of Athymic Nude Mice. Twenty-one days after the intra-pancreatic injection of 0.5×10^6 viable L3.6pl cells in 50 μ l HBSS, the pancreatic tumors reach the size of 5-6-mm. At that time, the mice are randomized to the following 8 treatments (n=10): (1) Control mice: administration of water diluted at 1:20 with DMSO-0.5% Tween 80 (diluent) by oral gavage 3 times per week, daily oral gavage with sterile water, and i.p. injections of PBS twice a week; (2) administration of diluent by oral gavage 3 times per week, daily oral gavage with sterile water, and twice weekly i.p. injections of gemcitabine (50 mg/kg); (3) oral gavage of AEE788 (50 mg/kg), 3 times per week, daily oral gavage with sterile water, and twice per week i.p. injections of PBS; (4) oral gavage of AEE788 (50 mg/kg) three times per week, daily oral gavage with sterile water, and twice per week i.p. injection of gemcitabine (50 mg/kg); (5) daily oral gavage of STI571 (50 mg/kg), diluent of AEE788 by oral gavage 3 times per week and i.p. injections of PBS twice per week; (6) daily oral STI571 (50 mg/kg), oral gavage of diluent for AEE788 3 times per week, and i.p. injections of gemcitabine (50 mg/kg) twice weekly; (7) combination of oral AEE788 (50 mg/kg) 3 times per week, daily STI571 (50 mg/kg), and twice per week i.p. injections of PBS; and (8) combination of oral AEE788 (50 mg/kg) 3 times per week, STI571 (50 mg/kg) 7 times per week, and twice per week i.p. injections of gemcitabine (50 mg/kg). All mice are treated for 4 weeks and killed on day 49 of the experiment.

For survival studies, 21 days after the intra-pancreatic injection of 1.0×10^6 tumor cells in 50 μ l HBSS, at which time the tumors in the pancreas exceeded 6- to 8-mm in diameter, the mice are randomized (n=10) to one of the 8 treatment groups, as described above. The mice are killed and necropsied when they became moribund. Survival is evaluated by the Kaplan-Meier method.

Necropsy Procedures and Histological Studies. In the first treatment study, the mice are killed on day 49 after tumor cell injection, weighted, and necropsied. Tumors growing in the pancreas are excised and weighed. For immunohistochemical staining procedures, one part of the tumor tissue is fixed in formalin and embedded in paraffin and the other is embedded in OCT compound (Miles, Inc., Elkhart, IN), rapidly frozen in liquid nitrogen, and stored at -70°C.

Immunohistochemical (IHC) Analysis to Detect EGF, VEGF, PDGF-BB, EGFR, VEGFR, PDGFR β , pEGFR, pVEGFR, pPDGF-R in Pancreatic Tumors. Paraffin-embedded pancreatic tumors of mice from all treatment groups are immunostained to evaluate the expression of EGF, VEGF, PDGF-BB, EGFR, VEGFR, PDGFR β , phosphorylated (p)EGFR, pVEGFR, and pPDGFR β . The sections are deparaffinized in xylene, dehydrated with alcohol and rehydrated in PBS. Endogenous peroxidase is blocked with 3% hydrogen peroxide in PBS. Samples are exposed to protein block (5% normal horse serum, 1% normal goat serum in PBS) and incubated overnight at 4°C with each primary antibody at the appropriate dilution. After 1 h incubation at room temperature with peroxidase-conjugated secondary antibody, positive reaction is detected by exposure to stable 3,3'-diaminobenzidine (DAB) (Phoenix Biotechnologies, Huntsville, AL). Slides are counterstained with Gill's #3 hematoxylin. Sections stained for immunoperoxidase or hematoxylin and eosin are examined in a microscope equipped with a three-chip-charged coupled device (CCD) color video camera. Digital images are captured using Optimas Image Analysis software (Media Cybernetics, MD).

IHC Determination of Proliferating Cell Nuclear Antigen (PCNA), CD31/PECAM-1 (Endothelial Cells) and TUNEL (Apoptosis). Paraffin-embedded tissues are used for IHC identification of proliferating cell nuclear antigen (PCNA). Frozen tissues used for identification of CD31/PECAM-1 are sectioned (8-10 μ m), mounted on positively charged slides, and air-dried for 30 min. Frozen sections are fixed in cold acetone (5 min), in acetone/chloroform (v/v; 5 min), and again in acetone (5 min), and washed with PBS. IHC procedures are performed as described previously (Hwang et al. in Clin Cancer Res 2003;9:6534-44). Control samples exposed to a secondary antibody alone show no specific staining. For the quantification of mean vessel density (MVD) in sections stained for CD31, 10 random 0.159-mm² fields at X100 magnification are captured for each tumor, and microvessels are quantified. For quantification of PCNA expression, the number of positive cells is counted in 10 random 0.159-mm² fields at X100 magnification. Analysis of apoptotic cells is performed by using a commercially available TUNEL kit (Promega) with the following modifications: Samples are fixed and incubated with an equilibration buffer followed by a reaction buffer (containing nucleotide mix and terminal deoxynucleotidyl transferase enzyme). Immunofluorescence microscopy is performed in a Zeiss Axioplan microscope (Carl Zeiss, Inc., Thornwood, NY) equipped with an HBO 100

mercury lamp, narrow bandpass filters to individually select for green, red, and blue fluorescence (Chroma Technology Corp., Brattleboro, VT). Images are captured using a cooled CCD Hamamatsu Orca camera (Hamamatsu Corp., Bridgewater, NJ) and Image Pro Analysis software (Media Cybernetics, Silver Spring, MD). Photomontages are prepared using Adobe Photoshop software (Adobe Systems, Inc., San Jose, CA). The number of TUNEL-positive cells in 10 random 0.159-mm² fields at X100 magnification is used to quantify apoptosis.

Double Immunofluorescence Staining for CD31/PECAM-1 and EGFR, pEGFR, VEGFR, pVEGFR, PDGFR β , pPDGFR β , Pericytes (desmin-positive cells), and TUNEL. Frozen sections of pancreatic tumors are mounted on slides and fixed. Immunofluorescence for CD31 is performed using Alexa594 conjugated secondary antibody, and samples are again blocked briefly in a blocking solution (5% normal horse serum and 1% normal goat serum in PBS) as described above and incubated with antibody against human EGFR, pEGFR, VEGFR, pVEGFR, PDGFR β , pPDGFR β , or desmin at 4°C overnight. After washes and blocking with blocking solution, samples are incubated with Alexa488 conjugated secondary antibody. Endothelial cells are identified by red fluorescence, and EGF-R, pEGFR, VEGFR, pVEGFR, PDGFR β , pPDGFR β and desmin positive cells (pericytes) are identified by green fluorescence. The presence of growth factor receptors and phosphorylated receptors on endothelial cells are detected by colocalization of red and green fluorescence, which appeared yellow.

The coverage of pericytes on endothelial cells is determined by counting CD31 positive cells in direct contact with desmin-positive cells and CD31-positive cells without direct association with desmin-positive cells in five randomly selected microscopic fields.

TUNEL-positive apoptotic cells are detected by localized green fluorescence within cell nuclei, and endothelial cells are identified by red fluorescence. Apoptotic endothelial cells are identified by yellow fluorescence within the nuclei. Quantification of apoptotic endothelial cells is expressed as the ratio of apoptotic endothelial cells to the total number of endothelial cells in ten 0.159-mm² fields at x100 magnification.

Statistical Analysis. Body weight, tumor weight, PCNA-positive cells, mean vessel density (CD31/PECAM-1), and TUNEL-positive cells are compared using the Mann-Whitney *U* test. Survival analysis is computed by the Kaplan-Meier method and compared by the Log rank test.

RESULTS

Therapy of Human Pancreatic Cancer Growing in the Cecum of Nude Mice. In the first set of experiments, the effect of treatment with AEE788, STI571, and gemcitabine alone and in various combinations is determined against well-established (5-6 mm) pancreatic tumors. The mice are killed and necropsied on day 49 of the study (Table 1). Tumor incidence in the pancreas is 100% in all treatment groups. None of the treatments significantly affects body weight. Control mice have the largest tumors (0.77 g). Treatment with STI571 or gemcitabine alone does not inhibit tumor growth, but mice treated with AEE788 have significantly smaller tumors (0.33g; p<0.001). The combination of AEE788 and gemcitabine or AEE788 and STI571 (but not STI571 and gemcitabine) significantly decrease tumor weight in the pancreas (0.19 g, p<0.0001, 0.33 g; p<0.001 vs control, and 0.71 g, respectively). Combining AEE788, STI571, and gemcitabine for therapy produces the most significant inhibition of tumor growth (0.14 g, p<0.0001 versus control).

Table 1. Therapy of L3.6pl human pancreatic cancer cells implanted in the pancreas of nude mice

Treatment	Body weight(g)		Tumor weight (g)	
	Median	(Range)	Median	(Range)
Control	24.8	(18.8-27.8)	0.77	(0.48-1.80)
Gemcitabine	25.7	(20.0-28.1)	0.78	(0.36-1.23)
STI571	23.5	(18.7-27.2)	0.96	(0.45-1.83)
STI571 + Gemcitabine	25.0	(21.1-28.1)	0.71	(0.42-1.35)
AEE788	26.2	(21.3-28.5)	0.33	(0.08-0.44) ^a
AEE788 + Gemcitabine	25.3	(22.1-28.8)	0.19	(0.05-0.40) ^b
AEE788 + STI571	24.1	(22.2-29.0)	0.33	(0.05-0.50) ^a
AEE788 + STI571 +				
Gemcitabine	24.0	(21.5-28.9)	0.14	(0.04-0.30) ^{b,c}

^aP<0.001 vs control.

^bP<0.0001 vs control.

^cP<0.05 vs AEE788 or AEE788 and STI571.

In the next survival study, treatment begins 21 days after the intrapancreatic injection of 1.0×10^6 L3.6pl cells. The pancreatic tumors measure 6-8 mm in diameter. Treatment continues until the mice become moribund, at which time they are killed. Survival is analyzed using the Kaplan-Meier method. All treatments other than STI571 alone or gemcitabine alone significantly prolong survival as compared to the control treatment group. Mice treated with the combination of AEE788, STI571, and gemcitabine have the greatest prolongation of survival.

Immunohistochemical Analysis of L3.6pl Pancreatic Tumors. Tumor sections are analyzed immunohistochemically for the expression of EGF, EGFR, and pEGFR, VEGF, VEGFR, and pVEGFR and PDGF-BB, PDGFR β and pPDGFR β . Treatment with AEE788, STI571, gemcitabine, or any of the combination treatments do not alter the expression level of EGF, VEGF, PDGF-BB, EGFR, VEGFR, and PDGFR by the tumor cells or in the stroma cells. The phosphorylation of EGFR and VEGFR (but not PDGFR) is significantly reduced in tumors from mice treated with AEE788 alone or any combination therapy including AEE788. In contrast, PDGFR β (but not EGFR or VEGFR) phosphorylation is inhibited in tumors from mice treated with STI571 alone or combination therapy including STI571. These data confirm that at the concentration administered to mice, the PTK inhibitors produces specific inhibition of their respective target receptors. The combination therapies with AEE788 and STI571 and with AEE788, STI571, and gemcitabine inhibits phosphorylation of all three receptors.

EGF-R, VEGFR, PDGFR, pEGFR, pVEGFR and pPDGFR on Tumor-associated Endothelial Cells. To determine whether tumor-associated endothelial cells express EGFR, VEGFR, PDGFR β , pEGFR, pVEGFR, or pPDGFR β a double immunofluorescence staining technique is used. Tumor-associated endothelial cells from all treatment groups express similar levels of EGFR, VEGFR, and PDGFR β . The phosphorylation of EGFR and VEGFR is diminished on endothelial cells from tumors of mice treated with AEE788 or combination treatments including AEE788.

Phosphorylation of the PDGFR β is decreased on endothelial cells from tumors of mice treated with STI571 or combination treatments including STI571. Administration of AEE788 and STI571

or AEE788, STI571, and gemcitabine inhibited phosphorylation of EGFR, VEGFR, and PDGFR β on tumor-associated endothelial cells.

Cell Proliferation (PCNA), Apoptosis (TUNEL), and Mean Vessel Density (MVD). Cell proliferation is evaluated by staining for PCNA. In tumors from control mice, the median number of PCNA-positive cells is 371 ± 88 . As shown in Table 2, treatment with gemcitabine alone or STI571 alone decreases the number of dividing PCNA-positive cells. A significant decrease of PCNA-positive cells is found in tumors from all other treatment groups, with the highest inhibition produced in tumors from mice treated with AEE788, STI571, and gemcitabine (155 ± 54 , $P<0.001$).

Table 2. Immunohistochemical analysis of L3.6pl human pancreatic cancer cells growing in the pancreas of nude mice

Treatment	Tumor cells		Endothelial cells	
	PCNA ^{a,c}	TUNEL ^{b,c}	CD31 ^c	TUNEL ⁺ (%) ^c
Control	371 ± 88	1 ± 1	46 ± 11	0 ± 0
Gemcitabine	305 ± 71	8 ± 3^f	38 ± 7	1 ± 1
STI571	301 ± 49	6 ± 2	37 ± 7	0 ± 0
STI571 + Gemcitabine	254 ± 48^e	11 ± 4^f	34 ± 8^d	0 ± 1
AEE788	233 ± 54^e	14 ± 4^f	25 ± 5^d	3 ± 3^e
AEE788 + Gemcitabine	187 ± 48^f	$22 \pm 7^{f,k}$	$28 \pm 7^{f,k}$	8 ± 6^e
AEE788 + STI571	204 ± 69^e	18 ± 6^f	21 ± 5^f	5 ± 5^e
AEE788 + STI571 +				
Gemcitabine	$155 \pm 54^{f,h}$	$30 \pm 10^{g,i,j}$	$16 \pm 6^{f,l}$	8 ± 5^e

^aPCNA, proliferating cellular nuclear antigen; ^bTUNEL, terminal deoxynucleotidyltransferase-mediated nick end labeling; ^cMedian \pm S.D.; ^d $P<0.05$ vs control; ^e $P<0.01$ vs control; ^f $P<0.001$ vs control; ^g $P<0.001$ vs control; ^h $P<0.05$ vs AEE788; ⁱ $P<0.01$ vs AEE788; ^j $P<0.05$ vs AEE788 + STI571; ^k $P<0.05$ vs AEE788.

- 18 -

The induction of apoptosis in the pancreatic tumors is evaluated by the TUNEL method (Table 2). In tumors from control-treated mice, the median number of apoptotic tumor cells is minimal (1 ± 1). The number of apoptotic cells in tumors from mice in all other treatment groups (except those treated with only STI571) increases, with the highest produced by therapy with the combination of AEE788, STI571, and gemcitabine (30 ± 10).

MVD in the tumors is determined by IHC staining with antibodies against CD31 (Table 2). The median number of CD31-positive tumor cells from control mice is 46 ± 11 . Treatment with gemcitabine alone or STI571 alone does not decrease MVD. The number of CD31-positive cells is significantly decreased in tumors from all other treatment groups, with the largest decrease in MVD in tumors from mice treated with AEE 788, STI571, and gemcitabine (16 ± 6) ($P<0.001$).

Immunofluorescence Double Staining for CD31/PECAM-1 and TUNEL It is determined whether therapy is associated with apoptosis of endothelial cells by using the CD31/TUNEL fluorescent double-labeling technique. Tumors from control mice have no apoptosis in tumor-associated endothelial cells. Treatment of mice with AEE788, STI571, and gemcitabine produce a median of $8 \pm 5\%$ apoptosis in tumor-associated endothelial cells (Table 2).

Further details of the study are described by Kenji Yokoi, Takamitsu Sasaki, Corazon D. Bucana, Dominic Fan, Cheryl H. Baker, Yasuhiko Kitadai, Toshio Kuwai, James L. Abbruzzese, and Isaiah J. Fidler in Cancer Research, 2005 Nov 15;65(22):10371-80, which publication is incorporated into the present specification by reference.

What is claimed is:


1. Use of a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity for the preparation of a medicament for the treatment of pancreatic cancer.
2. A method of treating a warm-blooded animal having pancreatic cancer comprising administering to the warm-blooded animal a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity in a quantity which is therapeutically effective against pancreatic cancer in which the dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity can also be present in the form of a pharmaceutically acceptable salt.
3. Use of a combination comprising (a) a compound which decrease the activity of the EGF and (b) a compound which decreases the activity of VEGF for the preparation of a medicament for the treatment of pancreatic cancer.
4. Use according to claim 3 wherein compound (b) is selected from bevacizumab and 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate.
5. Use according to claim 3 or 4 wherein compound (a) is selected from gefitinib and cetuximab.
6. A method of treating a warm-blooded animal having pancreatic cancer comprising administering to the warm-blooded animal a combination comprising (a) an inhibitor of the EGF-R tyrosine kinase activity and (b) an inhibitor of the VEGF-R tyrosine kinase activity in a quantity which is therapeutically effective against pancreatic cancer in which the components of the combination can also be present in the form of their pharmaceutically acceptable salts.
7. A combination comprising (a) a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity or, alternatively, a compound which decrease the activity of EGF and a compound which decreases the activity of VEGF and (b) at least one compound selected from an inhibitor of the PDGF-R tyrosine kinase activity and antineoplastic antimetabolites, wherein the active ingredients are present in each case in

free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

8. Combination according to claim 7 wherein compound (b) is selected from bevacizumab and 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate.

9. Combination according to claim 7 or 8 wherein compound (a) is selected from gefitinib and cetuximab.

10. The combination according to claim 7 comprising wherein compound (a) is a 7*H*-pyrrolo[2,3-d]pyrimidine derivatives of formula I



wherein

R_1 and R_2 are each independently of the other hydrogen, unsubstituted or substituted alkyl or cycloalkyl, a heterocyclic radical bonded via a ring carbon atom, or a radical of the formula $R_4-Y-(C=Z)-$ wherein R_4 is unsubstituted, mono- or disubstituted amino or a heterocyclic radical, Y is either not present or lower alkyl and Z is oxygen, sulfur or imino, with the proviso that R_1 and R_2 are not both hydrogen; or

R_1 and R_2 together with the nitrogen atom to which they are attached form a heterocyclic radical;

R_3 is a heterocyclic radical or an unsubstituted or substituted aromatic radical;

G is C_1-C_7 -alkylene, $-C(=O)-$, or C_1-C_6 -alkylene- $C(=O)-$ wherein the carbonyl group is attached to the NR_1R_2 moiety;

Q is $-NH-$ or $-O-$, with the proviso that Q is $-O-$ if G is $-C(=O)-$ or C_1-C_6 -alkylene- $C(=O)-$; and

X is either not present or C_1-C_7 -alkylene, with the proviso that a heterocyclic radical R_3 is

bonded via a ring carbon atom if X is not present;

or a salt of the said compounds,

and (b) at least one compound selected from N-phenyl-2-pyrimidine-amine derivatives, 5-fluorouracil, capecitabine, gemcitabine, methotrexate and edatrexate.

11. The combination according to claim 7 comprising (a) {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-(1-phenyl-ethyl)-amine and (b) at least one compound selected from N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and gemcitabine.
12. The combination according to claim 11 wherein N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine is used in the form of its mono-methanesulfonate salt.
13. Use of a combination according to any one of claims 7 to 12 for the preparation of a medicament for the treatment of pancreatic cancer.
14. A method of treating a warm-blooded animal having pancreatic cancer comprising administering to the warm-blooded animal a combination according to any one of claims 7 to 12 in a quantity which is therapeutically effective against pancreatic cancer in which the components of the combination can also be present in the form of their pharmaceutically acceptable salts.
15. A commercial package comprising (a) a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity or, alternatively, a compound which decrease the activity of EGF and a compound which decreases the activity of VEGF and (b) at least one compound selected from an inhibitor of the PDGF-R tyrosine kinase activity and antineoplastic anti-metabolites, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof, and optionally at least one pharmaceutically acceptable carrier; together with instructions for the simultaneous, separate or sequential use thereof in the treatment of pancreatic cancer.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 February 2007 (01.02.2007)

PCT

(10) International Publication Number
WO 2007/014335 A3

(51) International Patent Classification:

A61K 31/519 (2006.01) *A61K 31/445* (2006.01)
A61K 31/47 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2006/029439

(22) International Filing Date: 27 July 2006 (27.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/702,963 27 July 2005 (27.07.2005) US(71) Applicant (for all designated States except US): THE
UNIVERSITY OF TEXAS SYSTEM [US/US]; 201
West 7th Street, Austin, TX 78701 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): FIDLER, Isaiah, Josh
[US/US]; 4899 Montrose Blvd., Apt. 1113, Houston, TX
77006 (US).(74) Agent: JACKSON, Oona, A.; Novartis, Corporate Intellectual
Property Department, One Health Plaza, Bldg 104,
East Hanover, NJ 07936-1080 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report

(88) Date of publication of the international search report: 12 April 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATIONS COMPRISING GEMCITABINE AND TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER

(57) Abstract: The invention relates to a method of treating a warm-blooded animal having pancreatic cancer, in particular it relates to a method comprising administering to the warm-blooded animal having pancreatic cancer a dual inhibitor of the epidermal growth factor receptor (EGF-R) tyrosine kinase activity and the vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase activity, to a method comprising administering to the warm-blooded animal having pancreatic cancer a combination comprising (a) a compound which decrease the activity of the EGF and (b) a compound which decreases the activity of VEGF, to a combination comprising (a) a dual inhibitor of the EGF-R tyrosine kinase activity and the VEGF-R tyrosine kinase activity or, alternatively, a compound which decrease the activity of the EGF and a compound which decreases the activity of VEGF and (b) at least one compound selected from an inhibitor of the platelet derived growth factor receptor (PDGF-R) tyrosine kinase activity and antineoplastic anti-metabolites; to a method of treating a warm-blooded animal having pancreatic cancer comprising administering to the warm-blooded animal said combination; to the use of such a combination for the preparation of a medicament for the treatment of pancreatic cancer; and to a commercial package or product comprising such a combination together with instructions for the treatment of pancreatic cancer.

WO 2007/014335 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2006/029439

A. CLASSIFICATION OF SUBJECT MATTER	INV. A61K31/519	A61K31/47	A61K39/395	A61K31/445	A61P35/00
-------------------------------------	-----------------	-----------	------------	------------	-----------

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ANONYMOUS: "Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotin.."</p> <p>INTERNET ARTICLE, [Online]</p> <p>7 September 2004 (2004-09-07), XP002410261</p> <p>Retrieved from the Internet:</p> <p>URL:http://www.clinicaltrials.gov/ct/gui/show/NCT00091026;jsessionid=0266FF7B159A7F18EA31918F62B8BA79?order=6</p> <p>[retrieved on 2006-12-01]</p> <p>the whole document</p> <p>-----</p> <p style="text-align: center;">-/-</p>	1-15

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

5 December 2006

Date of mailing of the international search report

12/01/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Albayrak, Timur

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2006/029439

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	MEDSCAPE: "Pancreatic Cancer : An interview with Dr. Hedy Lee KIndler" INTERNET ARTICLE, [Online] 2005, pages 1-3, XP002410262 Retrieved from the Internet: URL: http://www.medscape.com/viewarticle/505573 [retrieved on 2006-12-01] page 2 -----	1-15
X	YOKOI KENJI ET AL: "Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice" NEOPLASIA (NEW YORK), vol. 7, no. 7, 1 July 2005 (2005-07-01), pages 696-704, XP002410235 ISSN: 1522-8002 the whole document -----	1-15
X	WO 2004/032937 A (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; BARGE ALAN [GB]) 22 April 2004 (2004-04-22) page 13 - page 14 page 11, line 17 - line 20 page 2, line 14 - line 25 page 3, line 18 - line 22 -----	1-15
X	BAKER C H ET AL: "Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 62, no. 7, 1 April 2002 (2002-04-01), pages 1996-2003, XP002373369 ISSN: 0008-5472 the whole document -----	1-15
X	WO 02/070008 A (IMCLONE SYSTEMS INC [US]; ROCKWELL PATRICIA [US]; GOLDSTEIN NEIL I [US]) 12 September 2002 (2002-09-12) claim 1.5 -----	2,3
Y	-----	11,13,14
X	WO 2004/014426 A (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; WEDGE STEPHEN ROBERT [GB]) 19 February 2004 (2004-02-19) claim 11 -----	1-15
X	WO 2005/027972 A2 (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; BOLD GUIDO [CH]; BRUEGGEN) 31 March 2005 (2005-03-31) claims 1,4 page 47 -----	1-15
	-----	-/-

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2006/029439

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/013541 A1 (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; BOLD GUIDO [CH]; CAPRARO) 20 February 2003 (2003-02-20) page 28, paragraph 3 page 25, paragraph 4 -----	2,3, 10-12
X	US 2004/248911 A1 (BOLD GUIDO [CH] ET AL) 9 December 2004 (2004-12-09) paragraphs [0171], [0185] -----	7,10,15
Y		11,13,14
P,X	WO 2006/065780 A2 (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; SIGMA TAU IND FARMACEUTI) 22 June 2006 (2006-06-22) the whole document -----	1,2
P,X	YOKOI KENJI ET AL: "Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model" CANCER RESEARCH, vol. 65, no. 22, November 2005 (2005-11), pages 10371-10380, XP002410236 ISSN: 0008-5472 the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2006/029439

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2004032937	A	22-04-2004		AU 2003269253 A1 BR 0315088 A CA 2501651 A1 CN 1703223 A EP 1551409 A1 JP 2006504723 T KR 20050055070 A MX PA05003595 A US 2006009418 A1		04-05-2004 16-08-2005 22-04-2004 30-11-2005 13-07-2005 09-02-2006 10-06-2005 03-06-2005 12-01-2006
WO 02070008	A	12-09-2002		BG 108214 A BR 0207977 A CA 2439933 A1 CZ 20032586 A3 EE 200300428 A EP 1379276 A1 HU 0303378 A2 JP 2005506288 T MX PA03007909 A NO 20033856 A PL 364719 A1 ZA 200307682 A		30-09-2004 01-02-2005 12-09-2002 18-08-2004 15-10-2004 14-01-2004 29-12-2003 03-03-2005 03-06-2005 03-11-2003 13-12-2004 13-01-2005
WO 2004014426	A	19-02-2004		AU 2003252976 A1 BR 0313117 A CA 2495489 A1 CN 1674938 A EP 1534338 A1 JP 2006500346 T KR 20050059060 A MX PA05001457 A US 2005245549 A1		25-02-2004 05-07-2005 19-02-2004 28-09-2005 01-06-2005 05-01-2006 17-06-2005 06-06-2005 03-11-2005
WO 2005027972	A2	31-03-2005		AU 2004273615 A1 BR PI0414698 A CA 2537991 A1 CN 1856327 A EP 1682181 A2 MX PA06003163 A		31-03-2005 28-11-2006 31-03-2005 01-11-2006 26-07-2006 05-06-2006
WO 03013541	A1	20-02-2003		BR 0211801 A CA 2453881 A1 CN 1538847 A EP 1416935 A1 HU 0401083 A2 JP 2005501077 T MX PA04001191 A NO 20040540 A NZ 530824 A PL 365783 A1 US 2004242600 A1 ZA 200400271 A		31-08-2004 20-02-2003 20-10-2004 12-05-2004 28-09-2004 13-01-2005 17-02-2005 05-02-2004 26-08-2005 10-01-2005 02-12-2004 01-11-2004
US 2004248911	A1	09-12-2004		NONE		
WO 2006065780	A2	22-06-2006		NONE		